Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Brendan W. Andersen"'
Autor:
Dean A Lee, Jeremiah L Oyer, Md Faqrul Hasan, Tayler J Croom-Perez, Liza D Robles-Carrillo, Sanjana Kumar, Brendan W Andersen, Brian P Tullius, Alicja J Copik, Amanda R Campbell, Thomas A Dieffenthaller, Catherine A Cash, Jonathan E Eloriaga, Meisam Naeimi Kararoudi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 12 (2023)
Background Inhibitory receptor T-cell Immunoreceptor with Ig and ITIM domains (TIGIT) expressed by Natural Killer (NK) and T cells regulates cancer immunity and has been touted as the next frontier in the development of cancer immunotherapeutics. Alt
Externí odkaz:
https://doaj.org/article/4c6550d3cfe540f09ffbff19f9a789fa
Autor:
Jeremiah L Oyer, Tayler J Croom-Perez, Liza D Robles-Carrillo, Faqrul Hasan, Sanjana Kumar, Brendan W Andersen, Javier A Rivera-Huertas, Brian P Tullius, Alicja J Copik
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/e63b7da5f22e44cc8ce962614d25561c
Autor:
Md Faqrul Hasan, Tayler J. Croom-Perez, Jeremiah L. Oyer, Thomas A. Dieffenthaller, Liza D. Robles-Carrillo, Jonathan E. Eloriaga, Sanjana Kumar, Brendan W. Andersen, Alicja J. Copik
Publikováno v:
Cancers; Volume 15; Issue 10; Pages: 2712
Treatments targeting TIGIT have gained a lot of attention due to strong preclinical and early clinical results, particularly with anti-PD-(L)1 therapeutics. However, this combination has failed to meet progression-free survival endpoints in phase III
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::290eca34a9ebaaa0d3a6549c6abaebe3